Mesure de la qualite de vie durant une chimiotherapie adjuvante du cancer colorectal

Translated title of the contribution: Adjuvant chemotherapy for colorectal cancer: Evaluation of the quality of life

Sarah Bellemare, F. Heyen, G. Martin, S. Dube

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Enhanced 5 year survival rates with adjuvant chemotherapy for colon and rectal caners are 5% and 95% respectively, according to recent meta-analysis. Despite the NIH consensus statement endorsing adjuvant chemotherapy, many clinicians regard such a seemingly small benefit not justworthy of the expense, inconvenience, discomfort and risk of treatment for their individual patient with colorectal carcinoma. The aim of this study is to evaluate these quality of life issues. The seven criteria considered most important were determined by interviews of treated patients, who emphasized the following quality of life parameters: nausea and vomiting, diarrhea, perineal dermatitis, asthenia, impairment of daily activity, family support, and difficulties of daily transportation to hospital. A numeric scale (1-5) was used to measure their answers (0 = hospitalization, 5 = no modification), and the non-parametric rank coefficient of Kendall was used to compare them. Twenty patients with colon cancer treated with Moertel's protocol and 5 patients with rectal cancer treated with Krook's protocol were evaluated. The study revealed a diminished quality of life for both patients with colon cancer (7 on a scale of 10) and those with rectal cancer (6 on the same scale). By using the same questionnaire at one week interval, the responses remained unchanged (p < 0.001). The effect of radiotherapy seems to be responsible for this difference. This study is one of the first to approach the quality of life from the real interested party's point of view: the patient.

Original languageFrench
Pages (from-to)711-715
Number of pages5
JournalAnnales de Chirurgie
Volume52
Issue number8
StatePublished - 1998
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Colorectal Neoplasms
Quality of Life
Rectal Neoplasms
Colonic Neoplasms
Asthenia
Dermatitis
Nausea
Vomiting
Meta-Analysis
Diarrhea
Consensus
Colon
Hospitalization
Radiotherapy
Survival Rate
Interviews

Keywords

  • Adjuvant chemotherapy
  • Colorectal carcinoma
  • Patients' point of view
  • Quality of life

ASJC Scopus subject areas

  • Surgery

Cite this

Mesure de la qualite de vie durant une chimiotherapie adjuvante du cancer colorectal. / Bellemare, Sarah; Heyen, F.; Martin, G.; Dube, S.

In: Annales de Chirurgie, Vol. 52, No. 8, 1998, p. 711-715.

Research output: Contribution to journalArticle

Bellemare, Sarah ; Heyen, F. ; Martin, G. ; Dube, S. / Mesure de la qualite de vie durant une chimiotherapie adjuvante du cancer colorectal. In: Annales de Chirurgie. 1998 ; Vol. 52, No. 8. pp. 711-715.
@article{0bb03b4d235447258550ed9940e860d0,
title = "Mesure de la qualite de vie durant une chimiotherapie adjuvante du cancer colorectal",
abstract = "Enhanced 5 year survival rates with adjuvant chemotherapy for colon and rectal caners are 5{\%} and 95{\%} respectively, according to recent meta-analysis. Despite the NIH consensus statement endorsing adjuvant chemotherapy, many clinicians regard such a seemingly small benefit not justworthy of the expense, inconvenience, discomfort and risk of treatment for their individual patient with colorectal carcinoma. The aim of this study is to evaluate these quality of life issues. The seven criteria considered most important were determined by interviews of treated patients, who emphasized the following quality of life parameters: nausea and vomiting, diarrhea, perineal dermatitis, asthenia, impairment of daily activity, family support, and difficulties of daily transportation to hospital. A numeric scale (1-5) was used to measure their answers (0 = hospitalization, 5 = no modification), and the non-parametric rank coefficient of Kendall was used to compare them. Twenty patients with colon cancer treated with Moertel's protocol and 5 patients with rectal cancer treated with Krook's protocol were evaluated. The study revealed a diminished quality of life for both patients with colon cancer (7 on a scale of 10) and those with rectal cancer (6 on the same scale). By using the same questionnaire at one week interval, the responses remained unchanged (p < 0.001). The effect of radiotherapy seems to be responsible for this difference. This study is one of the first to approach the quality of life from the real interested party's point of view: the patient.",
keywords = "Adjuvant chemotherapy, Colorectal carcinoma, Patients' point of view, Quality of life",
author = "Sarah Bellemare and F. Heyen and G. Martin and S. Dube",
year = "1998",
language = "French",
volume = "52",
pages = "711--715",
journal = "Journal de Chirurgie Viscerale",
issn = "1878-786X",
publisher = "Elsevier Masson",
number = "8",

}

TY - JOUR

T1 - Mesure de la qualite de vie durant une chimiotherapie adjuvante du cancer colorectal

AU - Bellemare, Sarah

AU - Heyen, F.

AU - Martin, G.

AU - Dube, S.

PY - 1998

Y1 - 1998

N2 - Enhanced 5 year survival rates with adjuvant chemotherapy for colon and rectal caners are 5% and 95% respectively, according to recent meta-analysis. Despite the NIH consensus statement endorsing adjuvant chemotherapy, many clinicians regard such a seemingly small benefit not justworthy of the expense, inconvenience, discomfort and risk of treatment for their individual patient with colorectal carcinoma. The aim of this study is to evaluate these quality of life issues. The seven criteria considered most important were determined by interviews of treated patients, who emphasized the following quality of life parameters: nausea and vomiting, diarrhea, perineal dermatitis, asthenia, impairment of daily activity, family support, and difficulties of daily transportation to hospital. A numeric scale (1-5) was used to measure their answers (0 = hospitalization, 5 = no modification), and the non-parametric rank coefficient of Kendall was used to compare them. Twenty patients with colon cancer treated with Moertel's protocol and 5 patients with rectal cancer treated with Krook's protocol were evaluated. The study revealed a diminished quality of life for both patients with colon cancer (7 on a scale of 10) and those with rectal cancer (6 on the same scale). By using the same questionnaire at one week interval, the responses remained unchanged (p < 0.001). The effect of radiotherapy seems to be responsible for this difference. This study is one of the first to approach the quality of life from the real interested party's point of view: the patient.

AB - Enhanced 5 year survival rates with adjuvant chemotherapy for colon and rectal caners are 5% and 95% respectively, according to recent meta-analysis. Despite the NIH consensus statement endorsing adjuvant chemotherapy, many clinicians regard such a seemingly small benefit not justworthy of the expense, inconvenience, discomfort and risk of treatment for their individual patient with colorectal carcinoma. The aim of this study is to evaluate these quality of life issues. The seven criteria considered most important were determined by interviews of treated patients, who emphasized the following quality of life parameters: nausea and vomiting, diarrhea, perineal dermatitis, asthenia, impairment of daily activity, family support, and difficulties of daily transportation to hospital. A numeric scale (1-5) was used to measure their answers (0 = hospitalization, 5 = no modification), and the non-parametric rank coefficient of Kendall was used to compare them. Twenty patients with colon cancer treated with Moertel's protocol and 5 patients with rectal cancer treated with Krook's protocol were evaluated. The study revealed a diminished quality of life for both patients with colon cancer (7 on a scale of 10) and those with rectal cancer (6 on the same scale). By using the same questionnaire at one week interval, the responses remained unchanged (p < 0.001). The effect of radiotherapy seems to be responsible for this difference. This study is one of the first to approach the quality of life from the real interested party's point of view: the patient.

KW - Adjuvant chemotherapy

KW - Colorectal carcinoma

KW - Patients' point of view

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0031767829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031767829&partnerID=8YFLogxK

M3 - Article

C2 - 9846419

AN - SCOPUS:0031767829

VL - 52

SP - 711

EP - 715

JO - Journal de Chirurgie Viscerale

JF - Journal de Chirurgie Viscerale

SN - 1878-786X

IS - 8

ER -